Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Robert J. Motzer, Homa Dastani et al.|The Lancet Oncology|2016Cited by 219
Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.David Cella, Robert J. Motzer, Viktor Gruenwald et al.|Journal of Clinical Oncology|2016Cited by 4